{"name":"Actinium Pharmaceuticals","slug":"actinium","ticker":"ATNM","exchange":"NYSE American","domain":"actiniumpharma.com","description":"Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research an","hq":"New York, NY","founded":0,"employees":"25","ceo":"Sandesh Seth","sector":"Targeted Radiotherapy / Hematologic Oncology","stockPrice":1.28,"stockChange":-0.01,"stockChangePercent":-0.78,"marketCap":"$40M","metrics":{"revenue":90000,"revenueGrowth":0,"grossMargin":100,"rdSpend":30045000,"netIncome":-38243000,"cash":47998000,"dividendYield":0,"peRatio":-2.7,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Iomab-B patent cliff ($0.0B at risk)","drug":"Iomab-B","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Actinium Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Actinium Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical pipeline and financial position.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Actinium Pharmaceuticals Announces $10 Million Registered Direct Offering","summary":"Actinium Pharmaceuticals announced a registered direct offering of $10 million in gross proceeds to support its clinical development programs.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"regulatory","headline":"Actinium Pharmaceuticals Receives FDA Clearance for Iomab-B Phase 3 Clinical Trial","summary":"Actinium Pharmaceuticals received clearance from the FDA to initiate a Phase 3 clinical trial for Iomab-B, its lead product candidate.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOTk44cVBzWHhPM19zQ0JtTUctRF8xakROUkFGc2lmZkd1TEdQT1VEb21sUHdGc0tFYzJBc1dKcW8xQlBnLXFvbGF6X0tJQkVTVU5ueEtGQk1jXzhXMXZtUXVDQUVnRy00NGZzamZ1ekR5eHZBWEdrVlJmUE5tbURFbTN5ZGltRnBTZDVYMmxPNUdrenMyZFVmZDdYQXFKNjlPQUc0ekhaNkVvYWh2b3NJaXhRQXprdjVNSnA3UUtuZ01hNUpoRy15MjROcU5UU1Z4a3BNSnJOYk5wSndQUXBMdUhwUFpvbzdjal9PaE1PNVMzUG5qLWRyNzFoZTBFdFY4bXJpdFhLZHprY3FhX0pKZlFIaFVnUWszSnZlVURjaVZVbnc4cDQxOHR3QlVrRzN5djdN?oc=5","date":"2026-04-06","type":"trial","source":"The AI Journal","summary":"Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - The AI Jo","headline":"Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechan","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNLVkzWDF1MWMwZnhxQnE5UXJCS3I5alFoR2J6TUZMWnRFMmFWZHp2SG00ajAxbm1tYzFSblZlOUVMTnJpV291eWt0alFRVUlrZnY1bnJyNDdVYzlzdDV5dkZobVd5dkllai1zV01TdmQtR1BweHZkRFg4ZHlVTU5kYjYweTd5VE55bks0azdvZVJwYUtCTDVqcS1EYjN1VEpNVUIyVnowak9hb1BtSFFhUmk0Y1lVMFF3?oc=5","date":"2026-02-13","type":"pipeline","source":"Stock Titan","summary":"Actinium Pharmaceuticals (NYSE: ATNM) CFO resigns; CEO adds finance role - Stock Titan","headline":"Actinium Pharmaceuticals (NYSE: ATNM) CFO resigns; CEO adds finance role","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPelZDb2NNNklyWXk3QkkyVllacV9wS0EybDFqa0plN0xKeG9qUDRfY29TaDdQTjlnV1p6cUphYUFJeEVSRFFfdXlmU2Z4MTFCUHpsaVFaa0hkcVVEeVkzb3pyVDNxeU42WlktaE91R2cxR1RwRVl6THdjSzBTbTdXdnVQWHp6eTN4S1lLOXg0V2VwSk1fWm12YQ?oc=5","date":"2025-12-22","type":"pipeline","source":"Yahoo Finance","summary":"Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance","headline":"Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZjV0NHdHcW9NamZqMms0YVc5cWhPaXoyRExLMS1YckVXczJRd2FIbWNrdmUtdzN6cFJ4VVRzak9samttZlZWd3FfQ3lyYS1qYzV3QWpqUHNqdTVqbkdxNzJYOWUyU3dldXBHY3Q4MDBUMGtFVXJRZktHVW1fWFV3QmFGbDlfV3ZYSnl4bElycDBFSHpZMjhDeTBLUlF4azZLaVpyS0JIUEN5aFdYT1VPNnYtV1ctekwy?oc=5","date":"2025-12-01","type":"pipeline","source":"Stock Titan","summary":"Actinium Pharma details ATNM-400 in resistant breast cancer | ATNM Stock News - Stock Titan","headline":"Actinium Pharma details ATNM-400 in resistant breast cancer | ATNM Stock News","sentiment":"neutral"},{"date":"2025-11-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxON1dudkhCY0VWajFxVzZGSlRPeWxEVXdJdTR3X1NETHo0aG5LcVVlX0FUNUxhaUp1bzU1NlNsUGc1YlRDOHNYanpRM0N5dTB1S2JqeWFqVTRUT195S3ZEWFc4VHVRNFgyc095WjFuWGFrTGxWWHRfZDVLRkp2cS1mRWFMTFh5VEQ1ZVp3RzFoclBrLU9PcElOc2FtcFltM0JOdkx1N3I0VEN6bzgwNlBlbXhhemh0elRyUk9mc29nbDdfY055MFRDUkVMNHk?oc=5","date":"2025-11-17","type":"pipeline","source":"TMX Newsfile","summary":"The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile","headline":"The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-13","type":"trial","source":"PR Newswire","summary":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Confer","headline":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, wi","sentiment":"neutral"},{"date":"2025-08-08","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-05-09","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-05-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOTldXRmhQc0RCdm9raUR1MTlBWThfRVl5eXdiclZfV29MVG5DUGRFRnJBN0hTSVB3SnczRVBfVVFLS1FUbGhWdGZRek95eEctQUF2UlFlRmtJOWE2RW1UajdsOEdLNlVoWkhXMGY3UlBRTzE5eFlDbi1sWkR0V3NrZGI3TzlXbGFpdGMxMGd3X0lXSTRaeE9qbmJSMjlWLW1lN1J5Vm5aY3UwblB2YWVlTkVlVEx4ZlZpdjVSVEFWV3pTbXFXS0NWZ3dCdjdwUFdtUFh0WG55UlB1azdBY2o0aTJ4a2NqUGhzS0tNYmtzUjk5b1lKYTN1eGVEX1FmSS1NRURhQ2JyVW44UG1GVFdaaV9QbEllanBuaHVMdTJ4UQ?oc=5","date":"2025-03-27","type":"pipeline","source":"PR Newswire","summary":"Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 - PR Newswire","headline":"Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Lever","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-27","type":"pipeline","source":"PR Newswire","summary":"Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipelin","headline":"Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA ","sentiment":"neutral"}],"patents":[{"drugName":"Iomab-B","drugSlug":"iomab-b","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer AG","Novartis AG","Bristol Myers Squibb Company"],"therapeuticFocus":["Targeted Radiotherapy","Hematologic Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":81000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":81000,"period":"2023-12-31"},{"value":81000,"period":"2023-12-31"},{"value":1030000,"period":"2022-12-31"},{"value":1030000,"period":"2022-12-31"},{"value":1144000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":30045000,"rdSpendHistory":[{"period":"2025-12-31","value":21124000},{"period":"2024-12-31","value":30045000},{"period":"2023-12-31","value":38670000},{"period":"2022-12-31","value":23135000}],"sgaSpend":15213000,"operatingIncome":-36247000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-36247000},{"period":"2024-12-31","value":-42121000},{"period":"2023-12-31","value":-51920000},{"period":"2022-12-31","value":-34104000}],"netIncome":-38243000,"netIncomeHistory":[{"period":"2025-12-31","value":-33887000},{"period":"2024-12-31","value":-38243000},{"period":"2023-12-31","value":-48818000},{"period":"2022-12-31","value":-33017000}],"eps":-1.09,"epsHistory":[{"period":"2025-12-31","value":-1.09},{"period":"2024-12-31","value":-1.27},{"period":"2023-12-31","value":-1.83},{"period":"2022-12-31","value":-1.37}],"cash":47998000,"cashHistory":[{"period":"2025-12-31","value":47998000},{"period":"2024-12-31","value":72904000},{"period":"2023-12-31","value":76677000},{"period":"2022-12-31","value":108910000}],"totalAssets":76899000,"totalLiabilities":43941000,"totalDebt":1694000,"equity":7834000,"operatingCashflow":-24580000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-24580000},{"period":"2024-12-31","value":-33072000},{"period":"2023-12-31","value":-47335000},{"period":"2022-12-31","value":8644000}],"capex":-104000,"capexHistory":[{"period":"2025-12-31","value":-104000},{"period":"2024-12-31","value":-11000},{"period":"2023-12-31","value":-153000},{"period":"2022-12-31","value":-366000}],"freeCashflow":-24684000,"dividendsPaid":null,"buybacks":null,"employees":25,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":2117000,"ebit":-6414000,"ebitda":-6208000,"period":"2025-12-31","revenue":0,"epsBasic":null,"netIncome":-5940000,"rdExpense":4297000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-6414000},{"sga":1534000,"ebit":-5692000,"ebitda":-5486000,"period":"2025-09-30","revenue":90000,"epsBasic":-0.16,"netIncome":-5131000,"rdExpense":4248000,"epsDiluted":-0.16,"grossProfit":null,"operatingIncome":-5692000},{"sga":2624000,"ebit":-7503000,"ebitda":-7299000,"period":"2025-06-30","revenue":0,"epsBasic":-0.22,"netIncome":-6878000,"rdExpense":4879000,"epsDiluted":-0.22,"grossProfit":null,"operatingIncome":-7503000},{"sga":8938000,"ebit":-16638000,"ebitda":-16433000,"period":"2025-03-31","revenue":0,"epsBasic":-0.51,"netIncome":-15938000,"rdExpense":7700000,"epsDiluted":-0.51,"grossProfit":null,"operatingIncome":-16638000},{"sga":2694000,"ebit":-7505000,"ebitda":-7301000,"period":"2024-12-31","revenue":0,"epsBasic":null,"netIncome":-6652000,"rdExpense":4811000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-7505000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.37,"netIncome":null,"rdExpense":null,"epsDiluted":-0.37,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.28,"previousClose":1.29,"fiftyTwoWeekHigh":1.95,"fiftyTwoWeekLow":0.95,"fiftyTwoWeekRange":"0.952 - 1.945","fiftyDayAverage":1.18,"twoHundredDayAverage":1.38,"beta":-0.11,"enterpriseValue":-5463507,"forwardPE":-2.7,"priceToBook":5.1,"priceToSales":446.22,"enterpriseToRevenue":-60.71,"enterpriseToEbitda":0.15,"pegRatio":0,"ebitda":-36064000,"ebitdaMargin":0,"freeCashflow":-12849375,"operatingCashflow":-24580000,"totalDebt":1694000,"debtToEquity":21.6,"currentRatio":6.2,"returnOnAssets":-35.2,"returnOnEquity":-167,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":5,"targetHighPrice":9,"targetLowPrice":2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.4,"institutionHeldPercent":20.7,"sharesOutstanding":31374994,"floatShares":30838625,"sharesShort":1093719,"shortRatio":6.49,"shortPercentOfFloat":3.5,"epsTrailing":-0.76,"epsForward":-0.48,"revenuePerShare":0,"bookValue":0.25,"officers":[{"age":61,"name":"Mr. Sandesh C. Seth M.B.A., M.S.","title":"CEO, Principal Financial Officer & Chairman"},{"age":null,"name":"Dr. Paul  Diamond Esq., Ph.D.","title":"Vice President of Patent & Legal Counsel"},{"age":59,"name":"Ms. Lynn M. Bodarky M.B.A.","title":"Chief Business Officer"},{"age":null,"name":"Dr. Madhuri  Vusirikala M.D.","title":"Vice President of Clinical Development BMT & Cellular Therapy"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.actiniumpharma.com","phone":"646 677 3870"}}